136 related articles for article (PubMed ID: 24524858)
1. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
3. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
[TBL] [Abstract][Full Text] [Related]
4. Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy.
Suzuki T; Aihara K
Math Biosci; 2013 Sep; 245(1):40-8. PubMed ID: 23648278
[TBL] [Abstract][Full Text] [Related]
5. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
6. Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer.
Suzuki T; Bruchovsky N; Aihara K
Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5045-59. PubMed ID: 20921011
[TBL] [Abstract][Full Text] [Related]
7. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.
Shimada T; Aihara K
Math Biosci; 2008; 214(1-2):134-9. PubMed ID: 18420226
[TBL] [Abstract][Full Text] [Related]
8. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer.
Hirata Y; Bruchovsky N; Aihara K
J Theor Biol; 2010 May; 264(2):517-27. PubMed ID: 20176032
[TBL] [Abstract][Full Text] [Related]
9. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modelling of prostate cancer growth and its application to hormone therapy.
Tanaka G; Hirata Y; Goldenberg SL; Bruchovsky N; Aihara K
Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5029-44. PubMed ID: 20921010
[TBL] [Abstract][Full Text] [Related]
11. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression.
Yang J; Zhao TJ; Yuan CQ; Xie JH; Hao FF
J Theor Biol; 2016 Sep; 404():66-72. PubMed ID: 27259386
[TBL] [Abstract][Full Text] [Related]
12. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
14. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
15. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
Malone S; Perry G; Segal R; Dahrouge S; Crook J
BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
17. Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer.
Hirata Y; Azuma S; Aihara K
Methods; 2014 Jun; 67(3):278-81. PubMed ID: 24680737
[TBL] [Abstract][Full Text] [Related]
18. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
19. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model.
Buhler KR; Santucci RA; Royai RA; Whitney SC; Vessella RL; Lange PH; Ellis WJ
Prostate; 2000 Apr; 43(1):63-70. PubMed ID: 10725867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
